Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accessibility, ADCC, ADCP, adenosine, Adimab, afucosylated, aggressive, agreeable, ahead, antigen, appraisal, bankrupt, bargain, Bayer, Biomedical, brochure, calendar, casdozokitug, cellular, chemokine, chosen, CIRT, Citigroup, Clawback, cloud, cluster, companion, compulsory, Computershare, consummated, consummation, content, correlated, Crimson, Cuban, cultivated, CVR, cytolytic, cytotoxicity, Dec, deceptive, depletion, diagnosed, diagnostic, differentiation, disaggregation, distant, divestiture, DPF, DRG, East, elicit, enterprise, enzyme, evidenced, explained, exploit, extracellular, FDIC, forma, France, garnering, Germany, GSK, HCC, hepatocellular, hybrid, immunological, Immunophage, immunosuppressive, inhibitory, Insider, interdisciplinary, interleukin, irrevocable, isotype, Italy, jeopardize, killer, LaNova, Lee, locoregionally, longevity, LOQTORZI, lucrative, mail, makewhole, McMichael, median, memory, metabolite, middle, Morgan, nationwide, NCCN, Neck, Newcomer, NIST, NK, nontransferable, nose, ONBODY, OS, overexpressed, PBC, pension, perpetual, physiologic, placenta, pregnancy, proper, proximity, purport, purpose, PVRIG, qualitative, quantitative, radiation, reaction, regain, reinsurance, residual, restraining, retroactive, retrospective, retrospectively, revert, revised, SCCHN, SEER, Shionogi, Silicon, skull, Spain, speed, split, surgery, suspected, TD, text, throat, tighter, Treg, unaudited, uncured, undisputed, upper, uptake, vaccinated, Vaccinex, Valley, Vice, WAC, yearly
Removed:
AB, Absent, Arzneimittel, ASC, Avastin, Bausch, bevacizumab, binomial, Biogen, Breakthrough, collaborator, comparability, comprised, computation, consecutive, contracting, correction, depression, earn, engineering, fifty, governor, hoping, humanized, infliximab, initiating, Innovent, lattice, Lomb, maturing, NASH, Pharma, PPAR, preponderance, qualification, qualifying, quarantining, recession, redeemed, redemption, regime, Remicade, requested, rolling, server, Shield, showed, simplified, spam, spread, STADA, straight, strained, subjectively, successive, Suzhou, thirty, widespread, Xbrane
Filing tables
Filing exhibits
Related press release
Associated CHRS transcripts
CHRS similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statements (Form S-3 Nos. 333-208625, 333-220590, 333-222698, and 333-268252) of Coherus BioSciences, Inc., |
(2) | Registration Statements (Form S-8 Nos. 333-200593, 333-203356, 333-209936, 333-216679, 333-222700, 333-229480, 333-236068, 333-251876, 333-262134, and 333-269291) pertaining to the BioGenerics, Inc. 2010 Equity Incentive Plan, as amended, the Coherus BioSciences, Inc. 2014 Equity Incentive Award Plan, and the Coherus BioSciences, Inc. 2014 Employee Stock Purchase Plan, and |
(3) | Registration Statements (Form S-8 Nos. 333-213077, 333-225616, 333-228274, 333-229479, 333-231329, 333-234601, 333-236065, 333-251877 and 333-262941) pertaining to the 2016 Employment Commencement Incentive Plan of Coherus BioSciences, Inc.; |
of our reports dated March 15, 2024, with respect to the consolidated financial statements of Coherus BioSciences, Inc. and the effectiveness of internal control over financial reporting of Coherus BioSciences, Inc. included in this Annual Report (Form 10-K) of Coherus BioSciences, Inc. for the year ended December 31, 2023.
/s/ Ernst & Young LLP
San Mateo, California
March 15, 2024